The Texas Supreme Court granted review for a Houston law firm on the losing end of a court of appeals decision that held 4,000 fen-phen plaintiffs are not collaterally estopped by a final judgment in a related case.
Fen-phen was a diet drug combination of drug combination fenfluramine and phentermine, shown to cause fatal pulmonary hypertension and heart valve problems. It was withdrawn from the market in 1997, and numerous mass tort lawsuits resulted in more than $13 billion in legal damages.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
